Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia

Title:Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia

Volume: 14 Issue: 8

Author(s): Ligia Mendes Soares, Jos Prickaerts, Humberto Milani, Elaine Del Bel, Harry Wilhelm Maria Steinbusch and Rubia Maria Weffort de Oliveira

Affiliation:

Keywords: Animal models, brain ischemia, stroke, phosphodiesterase inhibitors.

Abstract: Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.

Cite this article as:

Soares Mendes Ligia, Prickaerts Jos, Milani Humberto, Del Bel Elaine, Steinbusch Wilhelm Maria Harry and de Oliveira Maria Weffort Rubia, Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia, CNS & Neurological Disorders - Drug Targets 2015; 14 (8) . https://dx.doi.org/10.2174/1871527314666150909114249